July 3, 2023 11:00 AM EDTUpdated July 4, 07:57 AM
R&D
Pharma

J&J will ad­vance pso­ri­a­sis drug li­censed from Pro­tag­o­nist af­ter fuller Phase IIb read­out

Drew Armstrong

Executive Editor

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics will move in­to a Phase III tri­al, the health­care gi­ant said, af­ter ad­di­tion­al da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times